Endocannabinoids, lipid mediators that activate the same cannabinoid (CB) receptors as THC, the psychoactive component of marijuana, are well known to promote appetite and influence metabolism. Dr. Kunos and his laboratory have been at the forefront of discovering the underlying physiological mechanisms for these effects, and his work has identified potential new directions for CB receptor-based anti-obesity therapies without adverse psychiatric side effects. Join us to hear Dr. Kunos give an overview of this influential line of basic and translational research.
Targeting the Peripheral Cannabinoid System for Obesity Treatment
George Kunos, MD PhD